Navigation Links
Stryker Presents Results of the TREVO Prospective Clinical Study at the International Stroke Conference
Date:2/2/2012

KALAMAZOO, Mich., Feb. 2, 2012 /PRNewswire/ -- On February 2, at the Late-Breaking Science Session at the International Stroke Conference, Stryker announced the results of the TREVO Study (Thrombectomy REvascularization of large Vessel Occlusions in acute ischemic stroke). This was one of the first prospective, multi-center clinical studies of clot-removing stent retriever technology. Sixty patients were enrolled by seven leading stroke centers in Europe.

(Logo:  http://photos.prnewswire.com/prnh/20120202/NY46927LOGO )

The TREVO Study was designed to assess the ability of the Trevo® System to remove the blood clots that cause strokes and to restore blood flow to the brain. Revascularization was measured by an independent core lab.

The results were presented at the International Stroke Conference in New Orleans, LA by Professor Nils Wahlgren, co-Principal Investigator of the Study and Professor of Neurology at Karolinska University Hospital, Solna, Sweden. The results demonstrated high revascularization rates of 91.7% of patients. 46% of patients achieved a good outcome in just seven days and at 90 days, the good outcomes rate increased to 55%. These patients with good outcomes were functionally independent (modified Rankin score of 2 or less). A low symptomatic intracranial hemorrhage rate of 5% was also reported.

Professor Wahlgren commented: "The TREVO Study represents an important step forward in the evidence supporting the treatment of patients with moderate and severe strokes with mechanical thrombectomy devices, such as the Trevo System. The rigorous conduct of this prospective multicenter trial provides more confidence not only in patient selection, but in the successful procedural and clinical outcomes that can be achieved for these patients."

Clinical evidence remains key for wider
'/>"/>

SOURCE Stryker
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. STRYKER Signs Definitive Agreement to Acquire CONCENTRIC MEDICAL, Inc.
2. Stryker Orthopaedics Enters into Agreement with OrthoSensor for Intelligent Surgical Platform
3. Landmark Stryker Trial Establishes Coiling as Safe and Effective Treatment for Ruptured and Unruptured Aneurysms
4. Stryker Ends Distribution Agreement With Corin PLC
5. Stryker Announces Exclusive Collaboration With RegenLab
6. Stryker Launches VersiTomic G-Lok™
7. Stryker Orthopaedics Launches Its First iPad™ Apps for Surgeons, Available Through Apples App Store(SM)
8. Stryker Features Tissue-Preservation Hip Arthroscopy Platform, Sponsors Surgeon Education Events at the AAOS Annual Meeting
9. Fred Funk Becomes Spokesperson for Stryker Orthopaedics
10. Stryker Receives FDA 510(k) Clearance to Market Modular Dual Mobility Acetabular (Hip) System
11. Stryker Declares a $0.18 Per Share Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ), ... commercialization of products for central nervous system disorders, ... at the Society for Research on Biological Rhythms ... The first poster entitled Pleiomorphic Expression of ... insight into the challenges faced by individuals suffering ...
(Date:5/22/2012)... ALLEGAN, Mich., May 22, 2012  Perrigo Company ... final approval from the U.S. Food and Drug ... for butoconazole nitrate 2% vaginal cream, the generic ... submit a substantially complete ANDA with a paragraph ... marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical ...
(Date:5/22/2012)... Generics, a division of Prodigy Health Supplier Corporation ... generic equivalent of the branded drug Camptosar by ... Laboratories to develop a portfolio of oncology products. ... developed through the partnership that will add consistent ... market, which has experienced record levels of shortages ...
Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 1GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 2GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 4ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 1ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 1MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 3MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 4
... Planning for Phase 3 Trial Initiation on Track ... Limited (ASX: PGL; Nasdaq: PGLA) today announced it ... Contract Research,Organisation, to utilise their services for a ... the execution of the,Phase 3 clinical trial of ...
... Topic of Drug Repurposing and ... Indian Clinical Trial Strategy, ... biopharmaceutical company, announced today,that Chief Executive Officer, John Maki, and ... 234th American Chemical,Society National Meeting on Sunday, August 19, 2007. ...
Other Medicine Technology:Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88 2Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88 3Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 2Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 3
(Date:5/23/2012)... Reporter , , TUESDAY, May 22 (HealthDay News) -- ... procedure, which involves threading a camera through the ... But a new study has found that patients ... less time-consuming CT-based colon scan. Colonoscopy ... colon cancer screening. Computed tomography (CT) colonography -- ...
(Date:5/23/2012)... The number of viral infections during infancy is not ... new study from researchers in the Netherlands. While viral ... childhood, this association was due in part to decreased ... particularly rhinovirus, are thought to be a risk factor ... this association is due to the viruses themselves or ...
(Date:5/23/2012)... A tiny, resilient metal wire designed to gather ... patients with severe heterogeneous emphysema, a subtype of the ... lungs, according to the results of a multicenter international ... wire, called a lung volume reduction coil (LVRC), can ... place of more invasive procedures used to improve the ...
(Date:5/23/2012)... present findings on prostate cancer risk, screening, treatment ... of the American Urological Association May 19-23 in ... to provide expert comment for reporters covering the ... presented and their embargo dates include: , ... surgery hormone therapy , Embargoed until 10:30 a.m. ...
(Date:5/22/2012)... OR Bend Research Inc., a leading ... the expansion of its existing hot-melt extrusion ... 18mm Leistritz twin-screw mixer/extruder. , The ... existing 27mm Leistritz and 19mm Baker Perkins ... continuous high-shear wet-granulation capabilities. Many projects have ...
Breaking Medicine News(10 mins):Health News:Patients Prefer More Invasive Form of Colon Scan: Study 2Health News:Patients Prefer More Invasive Form of Colon Scan: Study 3Health News:Viral infections in infancy are not associated with wheezing symptoms in later childhood 2Health News:Tiny implanted coil improves lung function in patients with severe emphysema 2Health News:Tiny implanted coil improves lung function in patients with severe emphysema 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4
... A well-informed consumer will be a healthy one, too ... prescription filled is such a routine task, most people ... potentially a big mistake, according to medical experts -- ... cases, do real harm. , Pharmacists and health-care advocates ...
... to the Marketing Messages for Advair,and Xolair, According ... WALTHAM, Mass., Nov. 5 Decision Resources one ... on pharmaceutical and,healthcare issues, finds that physicians and ... asthma medicine to use.,Physicians indicate that brands conveying ...
... 9:00 a.m. EST -, VALENCIA, Calif., Nov. 5 ... results for the third quarter ended,September 30, 2008., ... were $69.1,million, compared to $75.6 million for the third ... in research and development,(R&D) expenses which totaled $55.6 million ...
... Stay Balanced Through the ... ... and New York Times best-selling author Ellie Krieger, of Food Network,fame, ... health. Yo-Plus contains live and active probiotic cultures,specifically designed for digestive ...
... CARY, N.C., Nov. 5 Cornerstone Therapeutics,Inc. ... focused on,developing and commercializing prescription medications for ... terms of the recently,completed merger between Cornerstone ... A. Collard, 42, president and chief executive,officer ...
... Inc. announced that,it reached a new high of more than ... case during the third quarter of 2008.,In addition, the quarter ... case activity with a leap of 64 %. Revenue and ... Through nine months of 2008,CardiacAssist has also set records in ...
Other Medicine News:Health News:When It Comes to Prescription Drugs, Get Smart 2Health News:When It Comes to Prescription Drugs, Get Smart 3Health News:Physicians Rank Schering-Plough's Marketing Messages for Asmanex as the Most Appealing in the Asthma Drug Market 2Health News:MannKind Corporation Reports Third Quarter Financial Results 2Health News:MannKind Corporation Reports Third Quarter Financial Results 3Health News:MannKind Corporation Reports Third Quarter Financial Results 4Health News:MannKind Corporation Reports Third Quarter Financial Results 5Health News:MannKind Corporation Reports Third Quarter Financial Results 6Health News:MannKind Corporation Reports Third Quarter Financial Results 7Health News:MannKind Corporation Reports Third Quarter Financial Results 8Health News:Healthy Eating Expert Ellie Krieger Joins Yoplait(R) Yo-Plus(TM) to Raise Awareness of Digestive Health 2Health News:Healthy Eating Expert Ellie Krieger Joins Yoplait(R) Yo-Plus(TM) to Raise Awareness of Digestive Health 3Health News:Cornerstone Therapeutics Announces New Board of Directors 2Health News:Cornerstone Therapeutics Announces New Board of Directors 3Health News:Cornerstone Therapeutics Announces New Board of Directors 4Health News:Cornerstone Therapeutics Announces New Board of Directors 5Health News:CardiacAssist, Inc. Announces Record Breaking Site Activity and Financial Results 2
... the revolutionary OxiMax® Pulse Oximetry System, ... Nellcor's best-in-class pulse oximetry with the ... OxiMax N-595 Pulse Oximeter is equipped ... technology, which enables it to withstand ...
The Model 340 is intended for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
A pocket-sized pulse oximeter. Perfect for the physician's office, emergency medicine, hospitals and clinics, and home health care....
... The Autocorr Pulse Oximeter with SAC ... unique patented software to extract SpO 2 ... in a new way. This cost-effective ... study functions as standard features, and a ...
Medicine Products: